No Data
Astrazeneca (AZN) Stock Moves -0.39%: What You Should Know
Daiichi Sankyo Gets Japanese Approval for Datroway
Here's Why Astrazeneca (AZN) Is a Strong Value Stock
Syncona: Achilles Announces Sale Of Technology Assets To AstraZeneca - Quick Facts
Achilles Therapeutics Sells Key Assets to AstraZeneca
Orient: Initiated a "Buy" rating for Hutchmed (China) with a Target Price of HKD 33.24.
Orient issued a research report predicting that Hutchmed (China) (00013) will have revenue of 680 million, 844 million, and 1 billion USD for 2024-2026, respectively. Based on comparable companies, a 4.4 times PS is given for the company in 2025, corresponding to a Target Price of 33.24 HKD, with an initial 'Buy' rating. Orient's main points are as follows: a Global layout of small molecule Innovative Drugs. The company was founded in 2000, and after more than twenty years of deep cultivation in the small molecule oncology field, it has three commercialized products and several late-stage clinical drugs, accumulating rich experience in commercial Operation, and partnering with...
loading...
Just Care Bears : I thought there’s a FDA approval going on on this today no news yet
Claudius NJIE Just Care Bears : yes good news is coming.
Claudius NJIE : pls run to at least 50